Earlier this year, a cluster of "research peptides" that have lived almost entirely in animal studies and online forums — BPC-157, GHK-Cu, TB-500, MOTS-c — appeared on ClinicalTrials.gov as registered, placebo-controlled human trials.[1][2][3][5] On the surface, that looked like the human evidence these compounds have always lacked was finally arriving.
It was not. All eight of these registrations trace to one sponsor at one hospital, and two of them say in their own submitted text that they are not real studies. The TB-500 record's Brief Summary opens with the sentence "This fictional study is an example of a ClinicalTrials.gov-style record."[3] A tesamorelin record in the same batch carries "(Mock Study)" directly in its registered title.[4] Two more are near-copies of real Eli Lilly programmes.
The remaining four — BPC-157, GHK-Cu, MOTS-c, and Melanotan II — carry no disclaimer, which is precisely why each one reads as credible when you find it on its own. We are treating the whole batch the same way: not as evidence that any of these trials exist.
- Two records in this batch self-identify as fictional or mock in text their own sponsor submitted.[3][4]
- All eight share one sponsor (Hudson Biotech), one site (Peking University Shenzhen Hospital, China), start dates clustered around February 2, 2026, and one contact email on a domain that does not match the sponsor.
- The same sponsor registered a Phase 3 of tirzepatide — a drug Eli Lilly already markets — and a retatrutide trial reusing Lilly's internal code "LY3437943."[6][7]
- A registration is not a result. Listing a trial on ClinicalTrials.gov requires no peer review and no proof that the study exists.[9]
- The evidence picture is unchanged: these peptides still have no credible human RCT data.
Quick facts
- Sponsor
- Hudson Biotech (Hudson Tianjin Biotechnology)
- Trial site
- One hospital, Shenzhen, China
- Registrations in batch
- 8
- Self-identified as fake
- 2 (TB-500, tesamorelin)
- Copies of real Lilly trials
- 2 (tirzepatide, retatrutide)
- Verified
- ClinicalTrials.gov API, August 15, 2026
What was actually registered
Four of the peptides our readers ask about most have ClinicalTrials.gov records. Here is what each record claims, at face value:
- BPC-157 — a Phase 2, double-blind, placebo-controlled trial in acute grade II hamstring strain, enrolling 120 participants, first posted February 27, 2026.[1]
- GHK-Cu — a Phase 2, vehicle-controlled, split-wound study of a topical copper-peptide gel for skin-wound re-epithelialization, enrolling 60 participants, first posted February 27, 2026.[2]
- TB-500 (thymosin β4 17-23 fragment) — a Phase 1/2 study of cardiovascular biomarkers in adults with stable atherosclerotic cardiovascular disease, enrolling 80 participants, first posted March 23, 2026.[3]
- MOTS-c — a Phase 2a study of insulin sensitivity in adults with prediabetes and overweight/obesity, enrolling 120 participants, first posted April 1, 2026.[5]
The NCT numbers resolve. The designs read coherently. The placebo and vehicle controls are exactly what rigorous evidence requires. Taken one at a time — which is how a vendor link or a forum post will show you one — any of these looks like the study people have been waiting years for.
Read them together, and three things fall apart. The TB-500 record contradicts itself on its own page. The batch it belongs to contradicts the rest. And the sponsor's wider portfolio contradicts the idea that a real research organisation is behind any of it.
Two of the records say they are fictional
The clearest evidence does not require any inference about motive. It is written into the registrations themselves.
NCT07487363, the TB-500 cardiovascular study, begins its Brief Summary with this sentence:
This fictional study is an example of a ClinicalTrials.gov-style record.
That is the sponsor's own submitted text, still live on the record.[3]
NCT07481734, a tesamorelin liver-fat study registered by the same sponsor at the same site, does not bury it in the summary at all. Its registered Brief Title reads:
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
"(Mock Study)" is part of the title as filed.[4]
Two further records in the batch reproduce real Eli Lilly programmes — one mirrors the SURMOUNT-1 tirzepatide protocol title, and another reuses Lilly's internal compound code "LY3437943" for retatrutide.[6][7] Internal development codes are company-specific; an unrelated sponsor filing one is not something that happens by accident.
That leaves four records with no disclaimer of any kind: BPC-157, GHK-Cu, MOTS-c, and Melanotan II.[1][2][5][8] Those are the four that get cited by vendors and clinics, and the four we ourselves originally covered as real. They share the sponsor, the site, the start dates, and the contact email with the two that admit to being examples. We do not treat them as credible.
Why a registration is not evidence
ClinicalTrials.gov is a registry, not a referee. Sponsors submit their own records; the registry's job is transparency — to publicly log what a study intends to measure — not to vouch for the science.[9] The site applies quality-control checks, but a listing is fundamentally a claim that someone intends to run a study. It is not verification that the study exists, that anyone is enrolling, or that any oversight body reviewed it. That is how a record can describe itself as fictional in its first sentence and still sit on the site, resolving to a working NCT number, months later.
This is the core point worth holding onto, and it generalises well beyond these eight records: an NCT number is not a credential. When a vendor, clinic, or article cites one, the useful questions are who the sponsor is, how many sites are involved, what else that sponsor has registered, and whether results were ever posted. Here, one search of the sponsor's other filings was enough.
What ties the batch together
Beyond the two admissions, the eight records share a set of features that no independent research programme would produce.
The sponsor — listed as Hudson Biotech (Hudson Tianjin Biotechnology) — registered all eight at the same single site, Peking University Shenzhen Hospital in Shenzhen, China. Start dates cluster around February 2, 2026. A single central contact email appears across the records, on a domain that does not match the sponsor's name. None has posted results, and none has been updated since spring 2026. The portfolio spans hamstring strains, skin wounds, cardiovascular biomarkers, prediabetes, vitiligo, liver fat, and obesity — unrelated indications that in a real organisation would need entirely different investigators, facilities, and expertise.
Two of the records are worth naming individually:
- A sponsor-run "Phase 3" trial of tirzepatide (NCT07481747) — a drug Eli Lilly already markets as Mounjaro and Zepbound — listing more than 2,500 participants at that one hospital, with a title mirroring Lilly's own SURMOUNT-1 programme.[6] A small sponsor independently running a pivotal trial of another company's marketed, patented drug is not how drug development works.
- A retatrutide trial (NCT07467447) reusing Eli Lilly's internal compound code, "LY3437943," with a near-verbatim Lilly protocol title.[7]
We are not in a position to say who filed these or why, and we are not asserting a motive. We do not need one. The records state their own nature, and the four undisclaimed peptide entries are inseparable from them.
What we are and are not saying. We are not naming an individual or alleging a crime. We are stating what the registry contains: eight records, one sponsor, one site, one contact address, two that describe themselves as fictional or mock studies, and two that copy real Eli Lilly trials. Every one of those is checkable on ClinicalTrials.gov today. The conclusion follows directly — none of these registrations is evidence that a trial of BPC-157, GHK-Cu, TB-500, MOTS-c, or Melanotan II exists.
What this changes about the evidence — nothing
It is tempting to read "BPC-157 is now in a placebo-controlled Phase 2 trial" as a sign that the compound has graduated into legitimacy. It has not. The evidence base for BPC-157, GHK-Cu, TB-500, and MOTS-c remains where our profiles describe it: heavily preclinical, concentrated in a small number of labs, and effectively without credible controlled human data.
These registrations changed nothing, and we have removed them from the evidence side of the ledger on every profile that mentioned them. We also published a correction to our own earlier coverage of the BPC-157 record, which we originally reported as the first BPC-157 randomized controlled trial. That was wrong, and it was wrong for the reason this article describes: we treated a database entry as though someone had vetted it.
For how to separate a credible study from a credible-looking listing, see our guide on how to verify a certificate of analysis — the same habits apply to reading a trial record.
What this means for you
If you use or are considering one of these peptides, here is how to weigh this.
If someone cites "the clinical trial," ask which NCT number. Then look it up, and look at what else that sponsor has registered. For these five peptides, that one step surfaces a sibling record announcing itself as fictional in its first sentence.
A registration is not a green light. Even a genuine listing tells you only that a study has been proposed and logged — not that the compound works, that it is safe, or that anyone is enrolling.
The underlying evidence is where it always was. These peptides are supported by animal work and, in GHK-Cu's case, small topical human studies. That is a real starting point and we describe it honestly on each profile. It is not clinical proof, and nothing in 2026 moved it.
Talk to a provider. If you are interested in any of these peptides for a specific condition, a knowledgeable healthcare provider can help you weigh the genuine evidence — which, for now, remains thin.
For the full evidence picture on each compound, see our profiles for BPC-157, GHK-Cu, TB-500, and MOTS-c.
References
- [1]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI.” 2026. Link
BPC-157, acute grade II hamstring strain. Phase 2, n=120. Single site (Peking University Shenzhen Hospital, China). Study first posted 2026-02-27. A registration record, not a result.
- [2]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults.” 2026. Link
GHK-Cu, topical wound healing. Phase 2, n=60. Same single site. Study first posted 2026-02-27.
- [3]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 1/2 Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease.” 2026. LinkRegistered trial (no results)
NCT07487363. TB-500 / thymosin β4 (17-23), cardiovascular biomarkers in stable ASCVD. Phase 1/2, n=80. Same single site. Study first posted 2026-03-23. The record's own Brief Summary opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Verified against the ClinicalTrials.gov API on August 15, 2026.
- [4]ClinicalTrials.gov (sponsor: Hudson Biotech). “Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study).” 2026. LinkRegistered trial (no results)
NCT07481734. "(Mock Study)" appears in the registered Brief Title, exactly as written above. Same sponsor and site as the rest of the batch. Verified against the ClinicalTrials.gov API on August 15, 2026.
- [5]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 2a Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c in Adults With Prediabetes and Overweight/Obesity.” 2026. Link
MOTS-c, prediabetes / insulin sensitivity. Phase 2a, n=120. Same single site. Study first posted 2026-04-01.
- [6]ClinicalTrials.gov (sponsor: Hudson Biotech). “Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities.” 2026. Link
Sponsor-run Phase 3 of tirzepatide — a drug already marketed by Eli Lilly as Mounjaro/Zepbound. n=2,539 listed, same single site. The title mirrors Lilly's SURMOUNT-1 program. Study first posted 2026-03-19.
- [7]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities.” 2026. Link
Retatrutide trial that reuses Eli Lilly's internal compound code 'LY3437943' and a near-verbatim Lilly protocol title. n=300, same single site. Study first posted 2026-03-12.
- [8]ClinicalTrials.gov (sponsor: Hudson Biotech). “A Phase 2 Study of Melanotan II as an Adjunct to Narrowband UV-B Phototherapy in Adults With Stable Nonsegmental Vitiligo.” 2026. Link
Melanotan II for vitiligo. Phase 2, n=60. Same single site. Study first posted 2026-02-27.
- [9]U.S. National Library of Medicine. “ClinicalTrials.gov — Background and About the Registry.” 2026. Link
ClinicalTrials.gov is a registry. Sponsors self-submit records; listing does not constitute review, validation, or endorsement of a study's scientific merit or results.
Stay informed
Get evidence-based peptide updates. No spam, no vendor pitches — just the research and regulatory changes that matter.
Related content
BPC-157
Full research profile covering mechanism, animal evidence, and the gap in credible human data.
PeptideTB-500
Recovery peptide often discussed alongside BPC-157. Research profile and evidence assessment.
PeptideGHK-Cu
Copper-peptide complex studied for skin and wound applications. Evidence and safety review.
PeptideMOTS-c
Mitochondrial-derived peptide explored for metabolic effects. What the evidence does and does not show.
GuideHow to Verify a Certificate of Analysis
The skeptical habits that help you tell a credible source from a credible-looking one.
NewsCorrection: The "First BPC-157 RCT"
We covered the BPC-157 registration as a real trial. Here is the correction, and what tipped us off.
Disclaimer
This article is for educational purposes only. BPC-157, GHK-Cu, TB-500, and MOTS-c are not FDA-approved drugs; they are not available by prescription and are not compoundable. The clinical-trial records described are self-submitted registrations, not peer-reviewed results, and two of them state in their own submitted text that they are not real studies. A ClinicalTrials.gov listing is not evidence of safety or efficacy. This is not medical advice or an endorsement of any peptide product. Always consult a licensed healthcare provider before using any peptide.